[Form 4] Atea Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 highlights for Atea Pharmaceuticals (AVIR): Director Jerome M. Adams reported several equity transactions on 20 June 2025.

• Common shares acquired: 29,600 shares were received upon conversion of previously vested restricted stock units (RSUs) at an effective price of $0.00 (code M). Adams now holds 62,750 AVIR shares directly.
• New equity awards granted:
• RSUs: 29,600 units granted (code A). They vest in a single installment on the earlier of the next annual meeting or the first anniversary of grant, subject to continued service.
• Stock options: 41,200 options granted with a $3.25 exercise price, expiring 19 June 2035. Vest monthly over 12 months, fully vested after one year.
• No derivative securities were sold; 29,600 RSUs were converted and the related derivative position is now zero.

Overall, the director increased his direct equity stake and received additional incentive-based awards, signaling continued alignment with shareholder interests.

Positive

• Director increased direct share ownership by 29,600 shares, bringing total holdings to 62,750, a potential show of confidence.
• Granted 41,200 options at $3.25, providing long-term incentive aligned with shareholder value creation.
• Additional 29,600 RSUs granted that vest within a year, further tying compensation to performance.

Negative

• None.

Insights

Equity Compensation Analyst

TL;DR – Director adds 29.6k shares, receives new 29.6k RSUs and 41.2k options at $3.25, boosting alignment.

The filing shows insider net share accumulation, not disposal. The zero-cost conversion of vested RSUs increased direct ownership to 62,750 shares, while newly granted RSUs and options extend equity exposure through 2035. Although the share count is modest versus Atea’s 83 million basic shares, insider buying—especially by a director—may be interpreted as a confidence signal. The $3.25 strike sits well below the 52-week high near $7 (as of recent trading), giving material upside leverage if the pipeline delivers. No negative governance flags appear; standard one-year vesting aligns with industry norms and encourages retention. Impact on float dilution is de minimis at <0.1%.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Adams Jerome M.

(Last) (First) (Middle)

225 FRANKLIN STREET

SUITE 2100

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Atea Pharmaceuticals, Inc. [ AVIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/20/2025		M		29,600	A	$0.00(1)	62,750	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	06/20/2025		A		29,600		(2)	(2)	Common Stock	29,600	$0.00	29,600	D
Stock Option (Right to Buy)	$3.25	06/20/2025		A		41,200		(3)	06/19/2035	Common Stock	41,200	$0.00	41,200	D
Restricted Stock Units	(1)	06/20/2025		M			29,600	(4)	(4)	Common Stock	29,600	$0.00	0	D

Explanation of Responses:

1. Restricted stock units convert into common stock on a one-for-one basis.

2. The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

3. The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 20, 2025, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date.

4. The restricted stock units vested in full on June 20, 2025.

	/s/ Andrea Corcoran, as Attorney-in-Fact for Jerome M. Adams	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many AVIR shares did Director Jerome M. Adams acquire on 20 June 2025?

He acquired 29,600 common shares through the conversion of vested RSUs.

What new equity awards did Jerome M. Adams receive from Atea Pharmaceuticals?

He received 29,600 new RSUs and 41,200 stock options with a $3.25 strike price expiring 19 June 2035.

What is the director’s total direct ownership in AVIR after the transactions?

Adams now directly owns 62,750 AVIR shares.

When do the newly granted RSUs vest?

They vest in a single installment on the earlier of the next annual shareholder meeting or one year after 20 June 2025, subject to continued service.

How does the option grant vest?

The 41,200 options vest monthly over 12 months following 20 June 2025 and become fully vested on the first anniversary of grant.